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One of the most common regions involved in the meningi-
omas tumorigenesis is chromosome 22q where the NF2
gene resides. The deficiency or loss of the NF2 gene prod-
uct, merlin/schwannomin, plays a role in tumor develop-
ment and metastatization. Conflicting results have been
reported on the prognostic value of merlin in meningio-
mas. Several studies have indicated NF2 gene inactivation
as an early tumorigenic event unrelated to the histological
grade or clinical behavior. On the contrary, the NF2 gene
alteration rate differs between the different histotypes. A
pathogenesis independent from the NF2 gene has been
suggested in meningothelial meningiomas. In the present
work, we studied the NF2 gene expression through real
time-PCR (RT-PCR) in 30 meningiomas. The average of
the NF2 gene expression of all meningiomas was consid-
ered as reference value. The average of expression of
WHO grade I and II meningiomas was higher than the
average of all meningiomas, whereas that of WHO grade
III meningiomas was lower. When we compared the NF2
gene expression in the different meningioma grades we did
not note a significant difference (P = 0.698) despite the ten-
dency to decrease from grade I to grade III. The average
expression of meningothelial meningiomas was higher
than the reference value, and that of non-meningothelial
meningiomas was lower. The difference in NF2 gene expre-
ssion between meningothelial and non-meningothelial
meningiomas was statistically significant (P = 0.013). Our
data supports the finding that alterations in NF2 gene
alteration are histotype related but not grade related.
Key words: meningioma, meningothelial, merlin, NF2, RT-
PCR.
INTRODUCTION
Meningiomas are frequent intracranial neoplasms (a
fourth of all primary tumors in this site) arising from the
leptomeningeal covering of the central nervous system
(CNS). They preferentially affect middle aged or elderly
women. Radiation exposure, hormonal and genetic factors,
particularly neurofibromatosis 2 syndrome (NF2), have
been implicated in their development and growth. Menin-
giomas initiation, both in NF2 associated and in sporadic
cases, is linked to the inactivation of the members of the
protein 4.1 superfamily, that is, NF2 gene product merlin/
schwannomin. Approximately 60% of sporadic meningio-
mas are caused by the LOH on chromosome 22q12 where
the NF2 tumor suppressor gene is localized; no causative
gene is known for the remaining 40%.1–8
Within the 4.1 superfamily, merlin shares the highest
degree of homology with a subgroup of proteins including
ezrin, radixin, and moesin (ERM proteins) that link the
actin cytoskeleton (by an actin-binding region in the
COOH-terminus) to cell membrane glycoproteins such as
CD44 (by its NH2-terminal residues) in polarized cells. The
NH2- and COOH- terminal halves of ERM proteins mutu-
ally interact intramolecularly to suppress their binding
activities. The COOH- terminal threonine phosphorylation
maintains ERM proteins in the active state by suppressing
the intramolecular interaction.5,7,9,10 The region of the mer-
lin with the greatest structural similarity to the ERM pro-
teins correspond to the its NH2-terminal two-thirds. The
merlin COOH-terminus lacks the conventional actin-
binding region of the ERM proteins. Contrary to ERM
proteins,  merlin  interacts  with  F-actin  through  the
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NH2-terminus.5,9,11–14 The similarity of merlin with the ERM
proteins indicates that its functions may be related to those
of the ERM proteins: organization of membrane exten-
sions and cell adhesion, membrane traffic, and cell signal-
ing. Indeed, merlin interacts, either directly or indirectly,
with components of cell junctions and with a number of
proteins influencing cell-growth regulation, including pax-
illin, erbB2, p21-activate kinase, and p53 (through MDM2
degradation). Biochemical studies showed that in the CNS
merlin also forms a complex with integrin β1 and with
Caspr/paranodin, an essential neuronal component of
paranodal axoglial junctions.5,7,9,10,13,15–17
Several experimental data demonstrated that merlin
overexpression results in a significant decrease in cell pro-
liferation, reversion of Ras-induced transformation, and
reduction in tumor formation in nude mice. In contrast, the
inactivation of the NF2 gene leads to the development of
cancer especially through loss of the contact-dependent
inhibition of the growth.13,14,18,19 The majority of the muta-
tions identified in the NF2 gene, result in a truncation of
the protein and are clinically associated with a severe phe-
notype; occasionally missense mutations associated with a
mild phenotype may occur.
The alterations in merlin functions did not show an
incontrovertible prognostic value in meningiomas. They
occurred in transitional and fibroblastic meningiomas
more often than in meningothelial variant.
In the present work, we studied the NF2 gene expres-
sion through real time-PCR (RT-PCR) in a group of 30
meningiomas and we evaluated its possible correlation
with tumor grade and histotype.
MATERIALS AND METHODS
Patients
Tissue specimens were obtained from 30 patients affected
by meningiomas surgically treated at the Neurosurgical
Service (Careggi Hospital, Florence, Italy) in which fresh
tumoral tissue was available for the RT-PCR. Seven (23%)
were from men and 23 (77%) were from women. Average
age at the time of the surgery was 54 years (range 29–76).
Twenty-nine  (97%)  meningiomas  were  intracranial  (one
of which was intraventricular; case no. 22 Table 1), the
remaining (3%) case was spinal meningioma (case no. 3;
Table 1). Two meningiomas (7%) were relapsed tumors
(case no.s 27, 28 Table 1); two meningiomas (7%) had mul-
tiple localizations (case no.s 1, 6 Table 1).
Real-time PCR
From each fresh surgical specimen we selected a fragment
macroscopically representative of the tumor. Successively,
we cut it in half: from one half several 5-µm frozen sections
stained with hematoxylin–eosin (HE) were obtained to
verify the adequacy of the specimens selected for RT-PCR
(presence of pathological tissue only); the other half was
immersed in RNAlater (QIAGEN, Valencia, CA, USA)
and kept overnight at +4°C and finally stored at −80°C until
it was analyzed. The thawed specimens were cut into small
pieces and homogenized. After proteinase K digestion
(250 µg/mL for 1 h at 37°C), total RNA was isolated with
6100 Nucleic Acid PrepStation (Applied Biosystems, Fos-
ter City, CA, USA). The RNA concentration and purity in
preparations was assessed spectrophotometrically by mea-
suring their absorbance at 260 nm and 280 nm. The RNA
fragmentation state was estimated with ethidium bromide-
stained 1% agarose gel. The fragment length of RNA was
>650 bp in all cases. Total RNA (500 ng) was subject to
reverse transcription to cDNA using High Capacity cDNA
Archive Kit (Applied Biosystems). The quantitative RT-
PCR was performed on an ABI PRISM 7000 Sequence
Detector System (Applied Biosystems). PCR products for
NF2 were detected using gene-specific primers and probes
labeled with reporter day FAM (Assay on Demand,
Applied Biosystems). GAPDH was used as endogenous
control gene for normalization. PCR reactions were car-
ried out in 96-well plate with 20 µL per well using 1× Taq-
Table 1 Histopathology and RT-PCR results
Case Histopathology RT-PCR
Who grade Histotype
1 I Fibrous −0.174
2 I Fibrous −0.896
3 I Fibrous 0.461
4 I Fibrous −0.198
5 I Fibrous −0.365
6 I Fibrous 0.501
7 I Fibrous −0.037
8 I Fibrous −0.219
9 I Meningothelial 0.361
11 I Meningothelial 0.385
12 I Meningothelial 0.432
13 I Meningothelial 0.376
14 I Meningothelial 0.339
15 I Meningothelial 0.09
16 I Secretory 0.277
17 I Transitional −0.054
18 I Transitional −0.372
19 I Transitional −0.051
20 I Angiomatous 0.08
21 II Atypical 0.457
22 II Atypical −0.337
22 II Atypical 0.07
23 II Atypical −0.326
24 II Chordoid 0.265
25 III Anaplastic −0.298
26 III Anaplastic −0.275
27 III Anaplastic 0.226
28 III Anaplastic −1.277
29 III Anaplastic 0.487
30 – Oncocytic 0.055
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Man Universal PCR MasterMix. After an incubation for
2 min at 50°C and 10 min at 95°C, the reaction continued
for 50 cycles at 95°C for 15 s and 60°C for 1 min.
The 2 –∆∆Ct method described by Livak and Schmittgen
was used to calculate fold expression levels relative to the
average value of the all meningiomas RNA specimens (the
calibrator).20 We chose the average expression of all men-
ingiomas as reference value to especially stress the stron-
ger difference of expression.
Histopathology
After the drawing of the small samples for RT-PCR, the
remaining tissues were routinely fixed in 10% buffered for-
malin and embedded in paraffin. Five-µm thick sections
were stained with HE for morphological evaluation. The
diagnostic criteria used were those indicated by the most
recently revised World Health Organization (WHO) clas-
sification of tumors of the nervous system.21
Statistical analysis
The shift of expression level of NF2 gene as estimated
through relative RT-PCR was calculated according to the
Kruskal–Wallis test. Data analysis was performed using
Primit Version 3.03 (McGraw-Hill, Milan, Italy, 1994) sta-
tistical package. A P-value ≤ 0.05 was considered to be sta-
tistically significant.
RESULTS
Cases and RNA extraction
Nineteen (63%) lesions were WHO grade I meningiomas
(eight fibrous, six meningothelial, three transitional, one
secretory and one angiomatous) (Fig. 1), five (17%) were
WHO grade II meningiomas (four atypical and one chor-
doid) (Figs 2,3), five (17%) were WHO grade III meningi-
omas (anaplastic) (Fig. 4) and one (3%) was an oncocytic
meningioma, a novel uncategorized rare variant showing
oncocytic differentiation (wide granular cytoplasm full of
numerous swollen mitochondria) and uncertain prognosis
(Fig. 5).22
Fig. 1 Secretory meningioma showing intra or extracytoplas-
mic round hyaline and eosinophilic bodies in a lesion
otherwise classifiable as meningothelial meningioma. HE.
Original magnification 400×.
Fig. 2 WHO II meningioma. Atypical meningioma showing
foci of necrosis. HE. Original magnification 200×.
Fig. 3 WHO II meningioma. Chordoid meningioma. HE.
Original magnification 200×.
Fig. 4 WHO III meningiomas. Anaplastic meningiomas
showing numerous mitoses. HE. Original magnification 400×.
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Real-Time PCR
RNA extraction was successful in all samples. The NF2
gene expression in all types of meningiomas was compared
to the average value of expression (reference value) of the
all meningiomas (Table 1).
The mean of NF2 relative gene expression of all WHO
grade I and II meningiomas showed an expression higher
(0.049 and 0.025, respectively) than the average of all men-
ingiomas used as calibrator. The mean of NF2 relative gene
expression of WHO grade III meningiomas showed an
expression lower (−0.227) than the calibrator (Fig. 6). The
only oncocytic meningioma had an expression higher than
the calibrator (0.055). When we compared the NF2 gene
expression between the different meningioma grades we
did not note a significant difference (P = 0.698) despite the
tendency to decrease from grade I to grade III (Fig. 6).
Analogously, there were not differences between the two
relapses and the primary meningiomas (P = 0.360). The
mean of NF2 relative gene expression of non-meningoth-
elial meningiomas was lower (−0.100) than the reference
value, that of meningothelial meningiomas (we considered
together meningothelial meningiomas and the only one
secretory  meningioma  because  secretory  meningioma  is
an infrequent meningioma subtype characterized by an
advanced epithelial differentiation in a lesion frequently
otherwise classifiable as meningothelial meningiomas,23
Fig. 1) was higher (0.306). Meningothelial meningiomas
(meningothelial meningiomas and secretory meningioma)
exhibited significantly higher NF2 gene expression com-
pared with those of non-meningothelial meningiomas
(P = 0.013 when all meningiomas were considered;
P = 0.018 when WHO grade I meningiomas only were
considered). Within each group of meningiomas, there is a
high variability of relative expression of each single case
(Table 1; Fig. 7).
DISCUSSION
In previous years, the genetic events involved in the molec-
ular pathogenesis of meningiomas begun to be defined.
One of the most common regions involved in the menin-
giomas tumorigenesis is chromosome 22q where the NF2
gene resides.24,25 Inactivating mutations of both alleles are
required in the tumorigenesis.26,27 In the familial setting
(NF2 syndrome), a germline mutation inactivates the first
allele; the second allele is inactivated by loss of chromo-
some or part of chromosome 22 on which the gene is
located in target cells. Somatic biallelic NF2 gene muta-
tions are implied for sporadic meningiomas. In some cases
the merlin expression has been demonstrated to be
reduced or absent also in absence of biallelic NF2 gene
inactivation suggesting that a post-translational regulation
of merlin may be involved in the loss of its expression.28–30
Fig. 5 Oncocytic meningioma: the
lesion is composed of sheets (A) of
rounded cells with wide granular eosi-
nophilic cytoplasm (B). HE. Original
magnification 100× (left), 400× (right).
A B
Fig. 6 NF2 relative expression in WHO grade I, II and III
meningiomas as compared with the average expression of all
meningiomas.
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The  majority  of  the  NF2  gene  mutations  results  in  a
non-functional, truncated protein.31 The mutations like
frameshift, nonsense and splice site alterations in the NH2-
terminal domain give rise to truncated or abnormal protein
in both NH2- and COOH-terminal domains. Other muta-
tions exclusively occur in the COOH-terminal domain. The
consequent loss of this region confers tumorigenicity con-
firming that COOH-terminus is essential for efficient anti-
oncogenic activity.32 The inability of merlin with altered
COOH-terminus to form intramolecular complexes was
associated with a failure to negatively regulate cell
growth.33 The in-frame deletions and missense mutation
involving one or few amino acids cause the loss of merlin
function.1 Some cases with NF2 gene mutations, not show-
ing merlin presence,31 suggest a possible decrease stability
of the mutant protein and consequently a difficult detec-
tion; moreover recent analysis of the only NF2 gene mis-
sense mutation demonstrated only a mildly decreased
protein half-life.30 It has been suggested that in some men-
ingiomas an abnormal activation of µ-calpain may cause
merlin loss by his proteolytic activity.34 Oxidative-stress
might cause µ-calpain activation. Based on these findings,
Kaneko et al. proposed an interesting scheme of meningi-
oma tumorigenesis:  first,  the  oxidative  stress  (e.g.,
due  to aging) induces Ca2+ mobilization, and Ca2+ activates
calpain; successively, the autolyzed and activated calpain
translocates from the cytoplasm to the plasma membrane;
merlin is then cleaved by the activated calpain, and this
cleavage product presumably transfers into the nucleus via
the perinuclear cytoplasm; as a consequence of this the sig-
nal pathway for cell adhesion and the contact inhibition
may be impaired, leading to meningiomas.35
Conflicting results have been reported with regard to
the possible prognostic value of merlin in meningiomas.
Several studies suggest that merlin loss is relatively equally
distributed among clinicopathological subsets. Indeed, it is
not associated with recurrences or with histopathological
features predicting unfavorable outcomes (i.e., brain inva-
sion, cellular proliferation, or anaplasia). Actually, the
majority of the previous studies have indicated the NF2
protein inactivation as an early tumorigenic event in spo-
radic and NF2-syndrome associated meningiomas.3,5,7,27,36,37
In contrast, the NF2 gene mutation rate differs between
histological subtypes of meningiomas. In 1995, Wellen-
reuther et al. demonstrated that NF2 gene mutation occurs
in 83% of transitional meningiomas and in 70% of fibro-
blastic meningiomas but in only 25% of meningothelial
meningiomas.36 More recently the hypothesis of a different
molecular route of pathogenesis independent of the NF2
gene pathway in meningothelial meningiomas has been
further supported.6,36–39
RT-PCR is an accurate method for the determination of
levels of specific DNA and RNA sequences in tissue sam-
ples. The amount of a specific RNA sequence consents to
evaluate the expression of a specific gene. Nevertheless,
the gene expression analyses do not assess the integrity or
the functionality of the translated protein. Consequently,
in our study we could not evaluate the stability and the
functionality of merlin. Nevertheless, our results on NF2
gene expression in different WHO grade meningiomas are
in agreement with the published literature. Although the
mean NF2 gene expression of the cases that we studied
seems to be reducing from WHO I to WHO III, there is an
extreme variability from case to case in each group.
Fig. 7 NF2 relative expression case
per case in WHO grade I ( ), grade II
( ) and grade III meningiomas ( )
and in oncocytic meningioma (case n°
30).
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Furthermore, analogously to previous studies that sup-
port an NF2 gene-independent pathogenesis histotype, we
observed a statistical difference in the NF2 gene expression
between meningothelial (meningothelial meningiomas and
secretory meningioma) and non-meningothelial meningio-
mas. Secretory meningioma showed high NF2 expression,
meaning that the similarity between these two histotypes
might be both morphological and molecular.
In conclusion our results indicate that NF2 gene expres-
sion alterations are not a mark of malignance in meningi-
omas and that meningothelial meningioma may arise
independently of NF2 gene alterations.
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